The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.47 as of 18 May 15:30
. The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of March 2021
.The P/E Ratio of Kobo Biotech Ltd is 0 as of March 2021
. The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 196.47 crore as of March 2021
.The Market Cap of Kobo Biotech Ltd is ₹ 17.63 crore as of March 2021
. The Revenue of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24
.The Revenue of Kobo Biotech Ltd is ₹ 0.02 crore as of Jun '24
. The EBITDA of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24
.The EBITDA of Kobo Biotech Ltd is ₹ -0.32 crore as of Jun '24
. The Net Profit of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of Jun '24
.The Net Profit of Kobo Biotech Ltd is ₹ -1.33 crore as of Jun '24
. The Dividend Payout of Bharat Immunological & Biological Corporation Ltd is 0 % as of March 2021
.The Dividend Payout of Kobo Biotech Ltd is 0 % as of March 2021.
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.
The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96.
The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.
About Kobo Biotech Ltd
Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA).
The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides.
The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.
FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd
Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Kobo Biotech Ltd?
Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr while Market cap of Kobo Biotech Ltd is 6 Cr
What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd?
The stock performance of Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd?
As of May 18, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.38. On the other hand, Kobo Biotech Ltd stock price is INR ₹2.58.
How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd compare?
To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Kobo Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.